-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VVVvy6xGyUP1cCbPjU/Sl8n108QGLBFMRc2Pt8Nzc18V+sV0VzWrmiYCo5IHNvIZ Jx+Vl9ep1PIhbgGiVd2KcA== 0000893220-00-000943.txt : 20000922 0000893220-00-000943.hdr.sgml : 20000922 ACCESSION NUMBER: 0000893220-00-000943 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20000731 FILED AS OF DATE: 20000810 DATE AS OF CHANGE: 20000906 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DECODE GENETICS INC CENTRAL INDEX KEY: 0001022974 STANDARD INDUSTRIAL CLASSIFICATION: 8731 IRS NUMBER: 043326704 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: SEC FILE NUMBER: 000-30469 FILM NUMBER: 692239 BUSINESS ADDRESS: STREET 1: LYNGHALSI 1 STREET 2: 011-354-577-1900 CITY: REYJKAVIK STATE: K6 ZIP: 94306-2155 MAIL ADDRESS: STREET 1: LYNGHALSI 1 STREET 2: REYKJAVIK CITY: ICELAND COMPANY DATA: COMPANY CONFORMED NAME: LAMOTTE ANDRE CENTRAL INDEX KEY: 0001117006 STANDARD INDUSTRIAL CLASSIFICATION: DIRECTOR FILING VALUES: FORM TYPE: 4 BUSINESS ADDRESS: STREET 1: C/O MEDICAL SCIENCE PARTNERS STREET 2: 161 WORCESTER RD., STE. 301 CITY: FRAMINGHAM STATE: MA ZIP: 01701 4 1 e4.txt FORM 4 - LAMOTTE 1 ------------------------------ OMB APPROVAL ------------------------------ OMB Number: 3235-0287 Expires: December 31, 2001 Estimated average burden hours per response ....... 0.5 ------------------------------ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [_] Check this box if no longer subject of Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) (Print or Type Responses) ________________________________________________________________________________ 1. Name and Address of Reporting Person* Lamotte Andre - - - -------------------------------------------------------------------------------- (Last) (First) (Middle) 161 Worcester Rd. - - - -------------------------------------------------------------------------------- (Street) Framingham, Massachusetts 01701 - - - -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Issuer Name and Ticker or Trading Symbol deCODE genetics, Inc. ("DCGN") ________________________________________________________________________________ 3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary) ________________________________________________________________________________ 4. Statement for Month/Year July, 2000 ________________________________________________________________________________ 5. If Amendment, Date of Original (Month/Year) ================================================================================ 6. Relationship of Reporting Person(s) to Issuer (Check all applicable) [xx] Director [_] 10% Owner [_] Officer (give title below) [_] Other (specify below) _ _______________________________________________________________________________ 7. Individual or Joint/Group Filing (Check Applicable Line) [xx] Form filed by One Reporting Person [_ ] Form filed by More than One Reporting Person ________________________________________________________________________________ ================================================================================ Table I -- NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED ================================================================================
6. 4. 5. Owner- Securities Acquired (A) or Amount of ship 3. Disposed of (D) Securities Form: 7. Transaction (Instr. 3, 4, and 5) Beneficially Direct Nature of 2. Code ------------------------------- Owned at End (D) or Indirect 1. Transaction (Instr. 8) (A) of Month Indirect Beneficial Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership (Instr. 3) (Month/Day/Year Code V (D) and 4) (Instr.4) (Instr. 4) - - - ----------------------------------------------------------------------------------------------------------------------------------- Medical Science Partners Common Stock 7/21/00 C 586,514 A 586,514 I(1) II, L.P. - - - ----------------------------------------------------------------------------------------------------------------------------------- Medical Science II Co- Investment, Common Stock 7/21/00 C 158,745 A 158,745 I(1) L.P. - - - ----------------------------------------------------------------------------------------------------------------------------------- - - - ----------------------------------------------------------------------------------------------------------------------------------- - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ ====================================================================================================================================
* If the form is filed by more than one reporting person, see instruction 4(b)(v). Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Potential persons who are to respond to the collection of Information contained in this form are not required to respond unless the form displays a currently valid OMB control (Over) number. SEC 1474 (3-99) 2 FORM 4 (CONTINUED) Table II -- DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED (e.g., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES) ================================================================================
10. 9. Owner- Number ship of Form Deriv- of Conver- 5. 7. ative Deriv- 11. ion Number of Title and Amount Secur- ative Nature or Derivative 6. of Underlying 8. ities Secur- of 1. Exer- 4. Securities Date Securities Price Bene- ity: In- Title ise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct of Deri- Price Trans- action or Disposed Expiration Date ------------------ Deriv- Owned (D) or Bene- vate 0f action Code of(D) (Month/Day/Year) Amount ative at End In- ficial Secur- Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner- ity ative (Month/ 8) 4, and 5) Date Expira- Number ity Month (I) ship (inst. Secur- Day/ ------- ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) f 4) 4) 4) - - - ----------------- ---------------------------------------------------------------------------------------------------------------- Medical Science Partners Series A Common II, L.P. Preferred 7/21/00 C 586,514 Immed Stock 586,514 -0- I(1) - - - ---------------- ------------------------------------------------------------------------------------------------------------------ Medical Science II Co- Series A Common Invest- Preferred 7/21/00 C 158,745 Immed Stock 158,745 -0- I(1) ment, L.P. - - - ----------------------------------------------------------------------------------------------------------------------------------- Medical Science Warrant(2) Partners Common II, L.P. 10/27/99 8/26/05 Stock 100,000 $1.00 100,00 I(1) - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------ - - - ------------------------------------------------------------------------------------------------------------------------------------
Explanation of Responses: (1) The reporting person is the Managing General Partner of Medical Science Partners II, L.P. and Medical Science II Co-Investment, L.P. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. (2) Upon closing of Issuer's public offering on July 21, 2000, the warrants exercisable for Series A Preferred Stock became exercisable for Common Stock. /s/ Andre Lamotte 8/7/00 - - - --------------------------------------------- ----------------------- **Signature of Reporting Person Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. Page 2 -----END PRIVACY-ENHANCED MESSAGE-----